AMAG buying once-bankrupt Lumara for up to $1bn
This article was originally published in Scrip
AMAG Pharmaceuticals has been on the lookout for assets to add to its bag of marketed products for the past few years and now the company will pay up to $1bn to buy Lumara Health, formerly KV Pharmaceutical, which emerged from bankruptcy a year ago.
You may also be interested in...
The company will conduct subgroup analyses to support ongoing use, but analysts believe Makena is unlikely to be pulled from the market when compounded progesterone is the only alternative therapy. Nevertheless, sales already are declining, since generics launched last year.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.